Generated: August 17, 2017
DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 072509
describes METHYLDOPA AND HYDROCHLOROTHIAZIDE
, which is a drug marketed by Parke Davis, Dava Pharms Inc, Par Pharm, Teva, Watson Labs, Sandoz, Purepac Pharm, Ivax Sub Teva Pharms, and Mylan, and is included in forty-three NDAs. It is available from one supplier. Additional details are available on the METHYLDOPA AND HYDROCHLOROTHIAZIDE profile page.
The generic ingredient in METHYLDOPA AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; methyldopa. There are thirty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the hydrochlorothiazide; methyldopa profile page.
Summary for NDA: 072509
|Formulation / Manufacturing:||see details|Complete Access Available with Subscription
Summary for product number 001
|Approval Date:||Jun 2, 1989||TE:||RLD:||No|
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.